Search research articles
Contact Us
Filters
Showing results (281-290 of 290) with videos related to
Page
of 29
Sort By:
You have reached the last page of results.
This site can display upto 290 results.
European Urology
|
August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
Tomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
The New England Journal of Medicine
|
August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapy
Howard I Scher, Karim Fizazi, Fred Saad, et al.
The Lancet. Oncology
|
February 11, 2019
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith, Chris Parker, Fred Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Matthew Smith, Johann De Bono, Cora Sternberg, et al.
European Urology
|
December 17, 2013
180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study
Alexander Bachmann, Andrea Tubaro, Neil Barber, et al.
Immunotherapy
|
November 11, 2020
Pasotuxizumab, a BiTE<sup>®</sup> immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, et al.
European Urology
|
August 19, 2015
A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study
James A Thomas, Andrea Tubaro, Neil Barber, et al.
The Journal of Urology
|
September 16, 2014
A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study
Alexander Bachmann, Andrea Tubaro, Neil Barber, et al.
The Lancet. Oncology
|
January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J Ryan, Matthew R Smith, Karim Fizazi, et al.
The New England Journal of Medicine
|
June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapy
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Page
of 29
Search research articles
Search
Showing results (281-290 of 290) with videos related to
Sort By:
Page
of 29
You have reached the last page of results.
This site can display upto 290 results.
European Urology
|
August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
Tomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
The New England Journal of Medicine
|
August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapy
Howard I Scher, Karim Fizazi, Fred Saad, et al.
The Lancet. Oncology
|
February 11, 2019
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith, Chris Parker, Fred Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Matthew Smith, Johann De Bono, Cora Sternberg, et al.
European Urology
|
December 17, 2013
180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study
Alexander Bachmann, Andrea Tubaro, Neil Barber, et al.
Immunotherapy
|
November 11, 2020
Pasotuxizumab, a BiTE<sup>®</sup> immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, et al.
European Urology
|
August 19, 2015
A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study
James A Thomas, Andrea Tubaro, Neil Barber, et al.
The Journal of Urology
|
September 16, 2014
A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study
Alexander Bachmann, Andrea Tubaro, Neil Barber, et al.
The Lancet. Oncology
|
January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J Ryan, Matthew R Smith, Karim Fizazi, et al.
The New England Journal of Medicine
|
June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapy
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Page
of 29